Arcus Biosciences Announces Clinical Supply Agreement With Aveo Oncology

RCUS•2026-07-22

Clinical supply agreement with Aveo Oncology

Arcus Biosciences Inc. said it has announced a clinical supply agreement with Aveo Oncology to evaluate casdatifan in combination with tivozanib for advanced kidney cancer patients.

Enrollment for the new ARC-20 cohort is expected to begin in Q4 2026.

Aveo will supply tivozanib; Arcus will sponsor the study; and each retains rights to compounds.

Arcus Biosciences Announces Clinical Supply Agreement With Aveo Oncology

Clinical supply agreement with Aveo Oncology

Related News

Encore Capital Group Announces Redemption Of All Outstanding 4.00% Convertible Senior Notes Due 2029

Goosehead Insurance Announces CEO Transition

Peoples Financial Corporation Reports Results For The Second Quarter Of 2026

IBM Releases Second-Quarter Results

Lazard Declares Quarterly Dividend Of $0.50 Per Share